RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in children, yet no vaccine is available. The sole licensed preventive treatment against RSV is composed of a monoclonal neutralizing antibody (palivizumab), which targets a conformational epitope located on the f...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine
Main Authors: Hervé, Pierre-Louis, Deloizy, Charlotte, Descamps, Delphyne, Rameix-Welti, Marie-Anne, Fix, Jenna, McLellan, Jason S., Eléouët, Jean-François, Riffault, Sabine
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698904/
https://ncbi.nlm.nih.gov/pubmed/27553073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2016.08.006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items